Renerve (ASX:RNV) EBITDA Margin %: -1,845.12% (As of Dec. 2025)


What is Renerve EBITDA Margin %?

Renerve ASX:RNV +1.27% EBITDA Margin % is -1,845.12% as of Dec. 2025. The stock has 5 warning signs investors should review. Among 936 Biotechnology companies, Renerve ranks worse than 83.65% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Renerve's EBITDA for the six months ended in Dec. 2025 was A$-3.03 Mil. Renerve's Revenue for the six months ended in Dec. 2025 was A$0.16 Mil. Therefore, Renerve's EBITDA margin for the quarter that ended in Dec. 2025 was -1,845.12%.

Renerve  (ASX:RNV) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Renerve EBITDA Margin % Related Terms

Renerve EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Renerve's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renerve EBITDA Margin % Chart

Renerve Annual Data
Trend Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
-300.35 -1,289.06 -1,437.29 -1,263.97

Renerve Semi-Annual Data
Jun22 Jun23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial 0.00 0.00 -1,528.43 -1,112.43 -1,845.12

ASX:RNV vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Renerve's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renerve EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renerve's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Renerve's EBITDA Margin % falls into.


Renerve EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Renerve's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-3.438/0.272
=-1,263.97 %

Renerve's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-3.026/0.164
=-1,845.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -1,845.12% mean?
Renerve (ASX:RNV) has a EBITDA Margin % of -1,845.12% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Renerve and its competitors. According to the industry distribution chart, Renerve ranks #783 out of 936 companies in the Biotechnology industry, placing it in the top 83.7%.
Is Renerve's EBITDA Margin % too high?
Renerve's current EBITDA Margin % is -1,845.12%. Based on the distribution chart, Renerve ranks #783 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Renerve's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Renerve ranks #783 out of 936 companies for EBITDA Margin %. This places Renerve in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Renerve and its competitors. Renerve's current EBITDA Margin % is -1,845.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renerve stock overvalued right now?
Renerve (ASX:RNV) has a current EBITDA Margin % of -1,845.12%. The current EBITDA Margin % is -1,845.12%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Renerve (ASX:RNV), the current EBITDA Margin % is -1,845.12% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Renerve Business Description

Address 157 Heidelberg Road, Northcote, VIC, AUS, 3070
Renerve Ltd specializes in developing a range of ready-to-use products that are cleaner, safer for repairing or replacing damaged peripheral nerves, resulting in good patient outcomes. Its product candidates include NervAlign Bionic Nerve, NervAlign Nerve Graft, and NervAlign Nerve Cuff [The NervAlign Nerve Guide Matrix, The NervAlign Nerve Conduit, The NervAlign Bionic Replacement Nerve]. The company operates in New Zealand and USA. Maximum of revenue is from USA.